DANONE (BSN.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:BSN - FR0000120644 - Common Stock
77.04 EUR
-0.36 (-0.47%)
BSN gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 59 industry peers in the Food Products industry. While BSN belongs to the best of the industry regarding profitability, there are concerns on its financial health. BSN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
BSN had positive earnings in the past year.
In the past year BSN had a positive cash flow from operations.
Each year in the past 5 years BSN has been profitable.
BSN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BSN's Return On Assets of 4.20% is fine compared to the rest of the industry. BSN outperforms 62.71% of its industry peers.
BSN has a Return On Equity of 11.59%. This is in the better half of the industry: BSN outperforms 64.41% of its industry peers.
BSN's Return On Invested Capital of 6.83% is fine compared to the rest of the industry. BSN outperforms 64.41% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BSN is in line with the industry average of 7.10%.
The 3 year average ROIC (6.38%) for BSN is below the current ROIC(6.83%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROIC | 6.83% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
1.3 Margins
Looking at the Profit Margin, with a value of 6.72%, BSN is in the better half of the industry, outperforming 72.88% of the companies in the same industry.
In the last couple of years the Profit Margin of BSN has remained more or less at the same level.
BSN's Operating Margin of 13.25% is fine compared to the rest of the industry. BSN outperforms 76.27% of its industry peers.
BSN's Operating Margin has declined in the last couple of years.
BSN's Gross Margin of 50.47% is fine compared to the rest of the industry. BSN outperforms 77.97% of its industry peers.
BSN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% |
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BSN is still creating some value.
BSN has more shares outstanding than it did 1 year ago.
BSN has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, BSN has an improved debt to assets ratio.
2.2 Solvency
BSN has an Altman-Z score of 2.54. This is not the best score and indicates that BSN is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of BSN (2.54) is better than 64.41% of its industry peers.
BSN has a debt to FCF ratio of 5.07. This is a neutral value as BSN would need 5.07 years to pay back of all of its debts.
The Debt to FCF ratio of BSN (5.07) is better than 69.49% of its industry peers.
A Debt/Equity ratio of 0.83 indicates that BSN is somewhat dependend on debt financing.
BSN has a worse Debt to Equity ratio (0.83) than 69.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Altman-Z | 2.54 |
ROIC/WACC1.06
WACC6.45%
2.3 Liquidity
A Current Ratio of 0.95 indicates that BSN may have some problems paying its short term obligations.
BSN has a Current ratio of 0.95. This is in the lower half of the industry: BSN underperforms 76.27% of its industry peers.
A Quick Ratio of 0.78 indicates that BSN may have some problems paying its short term obligations.
The Quick ratio of BSN (0.78) is worse than 61.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 |
3. Growth
3.1 Past
BSN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.47%.
BSN shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.17% yearly.
BSN shows a small growth in Revenue. In the last year, the Revenue has grown by 0.54%.
Measured over the past years, BSN shows a small growth in Revenue. The Revenue has been growing by 1.60% on average per year.
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
3.2 Future
BSN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.39% yearly.
The Revenue is expected to grow by 3.16% on average over the next years.
EPS Next Y8%
EPS Next 2Y7.34%
EPS Next 3Y7.61%
EPS Next 5Y6.39%
Revenue Next Year0.68%
Revenue Next 2Y1.86%
Revenue Next 3Y2.53%
Revenue Next 5Y3.16%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 20.60, BSN is valued on the expensive side.
BSN's Price/Earnings is on the same level as the industry average.
When comparing the Price/Earnings ratio of BSN to the average of the S&P500 Index (26.11), we can say BSN is valued slightly cheaper.
With a Price/Forward Earnings ratio of 18.42, BSN is valued on the expensive side.
Based on the Price/Forward Earnings ratio, BSN is valued a bit more expensive than the industry average as 64.41% of the companies are valued more cheaply.
The average S&P500 Price/Forward Earnings ratio is at 36.21. BSN is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.6 | ||
| Fwd PE | 18.42 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as BSN.
BSN's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.3 | ||
| EV/EBITDA | 11.06 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
BSN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.58
PEG (5Y)N/A
EPS Next 2Y7.34%
EPS Next 3Y7.61%
5. Dividend
5.1 Amount
BSN has a Yearly Dividend Yield of 2.78%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 3.35, BSN pays a bit more dividend than its industry peers.
Compared to an average S&P500 Dividend Yield of 2.32, BSN has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.78% |
5.2 History
The dividend of BSN has a limited annual growth rate of 1.58%.
Dividend Growth(5Y)1.58%
Div Incr Years3
Div Non Decr Years4
5.3 Sustainability
BSN pays out 74.99% of its income as dividend. This is not a sustainable payout ratio.
BSN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP74.99%
EPS Next 2Y7.34%
EPS Next 3Y7.61%
FRA:BSN (11/28/2025, 7:00:00 PM)
77.04
-0.36 (-0.47%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)
Earnings (Next)
Inst Owners55.49%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap52.49B
Revenue(TTM)27.36B
Net Income(TTM)1.84B
Analysts74.84
Price Target80.89 (5%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.78% |
Yearly Dividend2.1
Dividend Growth(5Y)1.58%
DP74.99%
Div Incr Years3
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.83%
PT rev (3m)4.66%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.33%
EPS NY rev (3m)0.8%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.14%
Revenue NY rev (3m)-0.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.6 | ||
| Fwd PE | 18.42 | ||
| P/S | 1.92 | ||
| P/FCF | 18.3 | ||
| P/OCF | 13.65 | ||
| P/B | 3.31 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.06 |
EPS(TTM)3.74
EY4.85%
EPS(NY)4.18
Fwd EY5.43%
FCF(TTM)4.21
FCFY5.47%
OCF(TTM)5.64
OCFY7.33%
SpS40.15
BVpS23.28
TBVpS-9.5
PEG (NY)2.58
PEG (5Y)N/A
Graham Number44.26
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROCE | 12.02% | ||
| ROIC | 6.83% | ||
| ROICexc | 8.36% | ||
| ROICexgc | 50.58% | ||
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% | ||
| FCFM | 10.49% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
ROICexc(3y)7.67%
ROICexc(5y)7.39%
ROICexgc(3y)52.44%
ROICexgc(5y)45.6%
ROCE(3y)10.98%
ROCE(5y)10.58%
ROICexgc growth 3Y19.7%
ROICexgc growth 5Y13.36%
ROICexc growth 3Y4.65%
ROICexc growth 5Y1.26%
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
F-Score8
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Debt/EBITDA | 2.71 | ||
| Cap/Depr | 77.72% | ||
| Cap/Sales | 3.57% | ||
| Interest Coverage | 23.53 | ||
| Cash Conversion | 78.8% | ||
| Profit Quality | 156.01% | ||
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 | ||
| Altman-Z | 2.54 |
F-Score8
WACC6.45%
ROIC/WACC1.06
Cap/Depr(3y)59.49%
Cap/Depr(5y)65.43%
Cap/Sales(3y)3.2%
Cap/Sales(5y)3.59%
Profit Quality(3y)220.86%
Profit Quality(5y)178.79%
High Growth Momentum
Growth
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
EPS Next Y8%
EPS Next 2Y7.34%
EPS Next 3Y7.61%
EPS Next 5Y6.39%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
Revenue Next Year0.68%
Revenue Next 2Y1.86%
Revenue Next 3Y2.53%
Revenue Next 5Y3.16%
EBIT growth 1Y3.81%
EBIT growth 3Y2.2%
EBIT growth 5Y-1.53%
EBIT Next Year35.38%
EBIT Next 3Y14.38%
EBIT Next 5Y10.92%
FCF growth 1Y12.42%
FCF growth 3Y6.14%
FCF growth 5Y3.12%
OCF growth 1Y12.55%
OCF growth 3Y3.31%
OCF growth 5Y2.15%
DANONE / BSN.DE FAQ
What is the fundamental rating for BSN stock?
ChartMill assigns a fundamental rating of 4 / 10 to BSN.DE.
What is the valuation status of DANONE (BSN.DE) stock?
ChartMill assigns a valuation rating of 3 / 10 to DANONE (BSN.DE). This can be considered as Overvalued.
How profitable is DANONE (BSN.DE) stock?
DANONE (BSN.DE) has a profitability rating of 7 / 10.
What are the PE and PB ratios of DANONE (BSN.DE) stock?
The Price/Earnings (PE) ratio for DANONE (BSN.DE) is 20.6 and the Price/Book (PB) ratio is 3.31.
Can you provide the expected EPS growth for BSN stock?
The Earnings per Share (EPS) of DANONE (BSN.DE) is expected to grow by 8% in the next year.